Our commitment to Oncology
Ipsen’s commitment to oncology is demonstrated by its growing portfolio of therapies aimed at improving the lives of patients with neuroendocrine tumors, prostate, bladder and kidney cancer.
Our commitment to endocrinology
Ipsen continues to develop innovative medicines in endocrinology, with specific investment in pituitary pathologies and growth disorders.
Our commitment to neurosciences
A leader in toxins and recombinant toxin engineering, Ipsen is a key player in the treatment of central nervous system disorders and continues to expand in aesthetic indications.
- @IpsenGroup Ipsen Brazil launches #VivendoComTNE, a website for Brazilian patients suffering from Neuroendocrine Tumours:… https://t.co/CkLnKNJMMX
- @IpsenGroup Ipsen delivers strong sales growth of 18.8% in the first half of 2017 and upgrades its guidance https://t.co/bZ7xlb7cVV
- @IpsenGroup RT @EFPIA: #WeWontRest until we provide the right support for our patients' needs. Thank you for your pledge @IpsenGroup https://t.co/Mq4Mk…
- @IpsenGroup Ipsen's #annualreport is available on line: discover CEO David Meek's vision on Ipsen in 2016 https://t.co/hP2Fr2VZMg
RESEARCH & DEVELOPMENT
Our commitment is based on a strengthened partnership policy, a promising pipeline, two specialized technological platforms and three benchmark R&D centers across the globe.